title: Targeted agents and combinations in ovarian cancer: where are we now?
abstract: Epithelial ovarian cancer is a heterogeneous disease with distinct histological subtypes characterized by different patterns of clinical behaviour. The identification of molecular pathways associated with individual subtypes has fuelled enthusiasm for the development of targeted therapies directed at specific subtypes of ovarian cancer. To date, the most successful targeted therapies in ovarian cancer to have undergone clinical development include anti-angiogenic agents and PARP inhibitors. Other promising areas of development include folate receptor antagonists, MEK and BRAF inhibitors in low-grade serous carcinoma, and immunotherapy. These novel therapeutic agents have the potential to maximize tumor efficacy, minimize toxicity and improve outcomes for women with epithelial ovarian cancer.
authors.affiliation: a Gynaecology Unit , The Royal Marsden NHS Foundation Trust , 203 Fulham Road, London , United Kingdom.
authors.forename: Jennifer
authors.initials: J
authors.lastname: McLachlan
authors.affiliation: a Gynaecology Unit , The Royal Marsden NHS Foundation Trust , 203 Fulham Road, London , United Kingdom.
authors.forename: Joao Paulo da Silveira Nogueira
authors.initials: JP
authors.lastname: Lima
authors.affiliation: a Gynaecology Unit , The Royal Marsden NHS Foundation Trust , 203 Fulham Road, London , United Kingdom.
authors.forename: Lucy
authors.initials: L
authors.lastname: Dumas
authors.affiliation: a Gynaecology Unit , The Royal Marsden NHS Foundation Trust , 203 Fulham Road, London , United Kingdom.
authors.forename: Susana
authors.initials: S
authors.lastname: Banerjee
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D058990:Molecular Targeted Therapy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D005493:Folic Acid Antagonists; D007211:Indoles; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D048493:Proto-Oncogene Proteins B-raf; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human; C482119:BRAF protein, human; C530716:nintedanib
keywords: Anti-angiogenic therapy; PARP inhibitor; immunotherapy; ovarian cancer; targeted therapy